# DPAGT1

## Overview
The DPAGT1 gene encodes the enzyme dolichyl-phosphate N-acetylglucosaminephosphotransferase 1, a critical transmembrane protein involved in the initial step of N-linked glycosylation. This enzyme is located in the endoplasmic reticulum and plays a pivotal role in the dolichol-linked oligosaccharide pathway by catalyzing the transfer of N-acetylglucosamine to dolichol-phosphate. The proper function of this enzyme is essential for the correct folding and processing of proteins, which are vital for cellular homeostasis and function. Mutations in the DPAGT1 gene can lead to congenital disorders of glycosylation and limb-girdle congenital myasthenic syndrome, underscoring its importance in human health (YusteCheca2017DPAGT1CDG:; Iqbal2012A).

## Structure
The DPAGT1 protein is a transmembrane enzyme involved in the initial step of N-linked glycosylation, catalyzing the transfer of N-acetylglucosamine to dolichol-phosphate. It is predicted to have a size of 408 amino acids and a molecular weight of 46 kDa (Würde2012Congenital). The protein structure includes 10 transmembrane domains, which are integral to its function in the endoplasmic reticulum (Iqbal2012A). These domains are crucial for the protein's role in the dolichol-linked oligosaccharide pathway (Iqbal2012A).

The DPAGT1 protein contains two postulated dolichol-binding sequences and four putative sites for N-glycosylation, indicating potential post-translational modifications (Würde2012Congenital). A signal peptide is predicted to remain on the functional protein, suggesting its involvement in targeting the protein to the membrane (Würde2012Congenital). Mutations in the transmembrane domains, such as p.L168P, can disrupt the helical conformation, affecting protein function and leading to congenital disorders of glycosylation (Iqbal2012A). The protein's structure and function are critical, as evidenced by the lethality of Dpagt1-null mice shortly after uterine implantation (Würde2012Congenital).

## Function
The DPAGT1 gene encodes the enzyme UDP-N-acetylglucosamine-dolichyl-phosphate N-acetylglucosamine phosphotransferase, which is integral to the process of N-linked glycosylation in human cells. This enzyme is located in the endoplasmic reticulum (ER) and catalyzes the initial step of the dolichol-linked oligosaccharide pathway. It transfers N-acetylglucosamine from cytosolic UDP-N-acetylglucosamine to dolichol-phosphate, forming dolichol-pyrophosphate-N-acetylglucosamine, a precursor for glycan assembly (YusteCheca2017DPAGT1CDG:; Iqbal2012A).

This glycosylation process is crucial for the proper folding, stability, and function of many proteins. It ensures that proteins are correctly folded and processed within the ER before they proceed to the Golgi apparatus. Proper glycosylation is essential for maintaining ER homeostasis and preventing ER stress, which can activate the unfolded protein response (UPR) (YusteCheca2017DPAGT1CDG:).

In the context of cancer, DPAGT1-mediated N-glycosylation is involved in the regulation of ADAM10, a protein that modulates HER2 shedding in breast cancer cells. This process affects protein stability and trafficking, highlighting the enzyme's role in cellular signaling and protein maturation (Yang2023Inhibition).

## Clinical Significance
Mutations in the DPAGT1 gene are associated with several clinical conditions, primarily congenital disorders of glycosylation (CDG) and limb-girdle congenital myasthenic syndrome (CMS). DPAGT1-CDG, also known as CDG-Ij, is a severe multisystem disorder characterized by developmental delays, intellectual disability, epilepsy, microcephaly, and hypotonia. These symptoms arise from defects in protein N-glycosylation, a process crucial for proper cellular function (YusteCheca2017DPAGT1CDG:; Iqbal2012A). 

In contrast, mutations in DPAGT1 can also lead to a limb-girdle CMS, which is marked by muscle weakness, particularly in the proximal limb muscles, and the presence of tubular aggregates in muscle biopsies. This condition is characterized by impaired neuromuscular transmission due to reduced acetylcholine receptor levels at the neuromuscular junction, resulting from abnormal glycosylation (Belaya2012Mutations). 

The clinical spectrum of DPAGT1-related disorders is broad, with variations in severity and symptoms. Some individuals with DPAGT1 mutations may present with milder phenotypes, including moderate intellectual disability and balance problems, highlighting the diverse impact of these genetic alterations (Iqbal2012A).


## References


[1. (Belaya2012Mutations) Katsiaryna Belaya, Sarah Finlayson, Clarke R. Slater, Judith Cossins, Wei Wei Liu, Susan Maxwell, Simon J. McGowan, Siarhei Maslau, Stephen R.F. Twigg, Timothy J. Walls, Samuel I. Pascual Pascual, Jacqueline Palace, and David Beeson. Mutations in dpagt1 cause a limb-girdle congenital myasthenic syndrome with tubular aggregates. The American Journal of Human Genetics, 91(1):193–201, July 2012. URL: http://dx.doi.org/10.1016/j.ajhg.2012.05.022, doi:10.1016/j.ajhg.2012.05.022. This article has 122 citations.](https://doi.org/10.1016/j.ajhg.2012.05.022)

[2. (Yang2023Inhibition) Muwen Yang, Li, Lingzhi Kong, Shumei Huang, Lixin He, Pian Liu, Shuang Mo, Xiuqing Lu, Xi Lin, Yunyun Xiao, Dongni Shi, Xinjian Huang, Boyu Chen, Xiangfu Chen, Ying Ouyang, Li, Chuyong Lin, and Libing Song. Inhibition of dpagt1 suppresses her2 shedding and trastuzumab resistance in human breast cancer. Journal of Clinical Investigation, July 2023. URL: http://dx.doi.org/10.1172/jci164428, doi:10.1172/jci164428. This article has 3 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1172/jci164428)

[3. (YusteCheca2017DPAGT1CDG:) Patricia Yuste-Checa, Ana I. Vega, Cristina Martín-Higueras, Celia Medrano, Alejandra Gámez, Lourdes R. Desviat, Magdalena Ugarte, Celia Pérez-Cerdá, and Belén Pérez. Dpagt1-cdg: functional analysis of disease-causing pathogenic mutations and role of endoplasmic reticulum stress. PLOS ONE, 12(6):e0179456, June 2017. URL: http://dx.doi.org/10.1371/journal.pone.0179456, doi:10.1371/journal.pone.0179456. This article has 22 citations and is from a peer-reviewed journal.](https://doi.org/10.1371/journal.pone.0179456)

[4. (Iqbal2012A) Zafar Iqbal, Mohsin Shahzad, Lisenka E L M Vissers, Monique van Scherpenzeel, Christian Gilissen, Attia Razzaq, Muhammad Yasir Zahoor, Shaheen N Khan, Tjitske Kleefstra, Joris A Veltman, Arjan P M de Brouwer, Dirk J Lefeber, Hans van Bokhoven, and Sheikh Riazuddin. A compound heterozygous mutation in dpagt1 results in a congenital disorder of glycosylation with a relatively mild phenotype. European Journal of Human Genetics, 21(8):844–849, December 2012. URL: http://dx.doi.org/10.1038/ejhg.2012.257, doi:10.1038/ejhg.2012.257. This article has 23 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1038/ejhg.2012.257)

[5. (Würde2012Congenital) A.E. Würde, J. Reunert, S. Rust, C. Hertzberg, S. Haverkämper, G. Nürnberg, P. Nürnberg, L. Lehle, R. Rossi, and T. Marquardt. Congenital disorder of glycosylation type ij (cdg-ij, dpagt1-cdg): extending the clinical and molecular spectrum of a rare disease. Molecular Genetics and Metabolism, 105(4):634–641, April 2012. URL: http://dx.doi.org/10.1016/j.ymgme.2012.01.001, doi:10.1016/j.ymgme.2012.01.001. This article has 42 citations and is from a peer-reviewed journal.](https://doi.org/10.1016/j.ymgme.2012.01.001)